BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Gyala Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Gyala Therapeutics's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07471789-2868@assetmemo.bio
DTSTAMP:20261121T005935Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:CART84: Phase 1/2 readout est. (NCT07471789)
DESCRIPTION:CART84\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Safety and
  Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leu
 kemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).\nEstimate
 d primary completion: 31 May 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/cart84#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07471789
URL:https://assetmemo.bio/drug/cart84#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
